According to Axis Direct, Caplin Point Laboratories has broken decisively out of a multi-week consolidation phase that had developed around the ₹2,700 level. The stock was trading at ₹2,814.00 on September 7, 2026, representing only a 3% decline from its 52-week high of ₹2,874.00 hit on September 3, 2026. The technical setup shows the stock trading above all key moving averages - 20-day, 50-day, 100-day and 200-day simple moving averages - with these indicators trending higher alongside the price action. The weekly Relative Strength Index (RSI) is trending higher, indicating strengthening bullish momentum. Recent trading sessions have shown the stock moving within a range of ₹2,778.00 to ₹2,836.00 with significantly reduced volume of -84.21% compared to average volume.
The stock has delivered impressive returns across multiple timeframes, with 3% gains in the past week and 9% over one month. Over the past three months, Caplin Point Laboratories has surged 32%, while the six-month performance stands at 68%. The longer-term performance remains robust, with the stock adding 29% over the past year and generating multibagger returns of 233% for investors over the past five years. The stock's 52-week low stands at ₹1,522.45, a level touched in March 2026.
Axis Direct has specified a buy range of ₹2,750-2,696 with a stop loss at ₹2,490 and upside potential of 17-19%. Based on the technical setup, the brokerage sees potential for the stock to move towards ₹3,185-₹3,230 levels. The recommended holding period is 3-4 weeks for this technical setup. The breakout has been accompanied by a significant surge in volume, indicating increased market participation and supporting the strength of the move. Recent technical analysis suggests potential support levels at ₹2,781, ₹2,500, ₹2,331, ₹2,069, ₹1,965, ₹1,853, ₹1,761, ₹1,661, ₹1,553, and ₹1,500.30 if the trend reverses from current levels.
Last month, the US FDA conducted an unannounced inspection of Caplin Point Laboratories' injectable and ophthalmic manufacturing facility at Gummidipoondi between August 13-21, 2026. The company received Form 483 containing 10 observations, which were procedural in nature and did not pertain to data integrity. The company has scheduled its 35th Annual General Meeting for September 25, 2026, with the Board recommending a final dividend of ₹4 per equity share, taking the total FY26 dividend to ₹8 per share (400%). Shareholders must be on records as of September 18, 2026, to be eligible for the final dividend payout.
For the quarter ended June 30, 2026, Caplin Point Laboratories reported strong financial results with revenue from operations at ₹610.36 crores, registering year-on-year growth of 19.63% compared with ₹510.22 crores in the corresponding quarter of the previous year. The company's net profit increased to ₹179.09 crores, marking a YoY growth of 18.79% from ₹150.76 crore in the same quarter of the previous year.
